An official website of the United States government
Home
Name
Niraparib
Alternate Names
MK-4827
Zejula
Abbreviations
None
Category
Chemotherapy
Subcategory
PARP inhibitor
NSC Number
None
Primary Site
Histology
None
Remarks
10/25/2019 FDA approved Zejula (niraparib) for treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer.
3/28/2017: The U.S. Food and Drug Administration approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
May 1, 2020 FDA has approved a supplemental New Drug Application for Zejula (niraparib) an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a mono¬therapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
3/28/2017: The U.S. Food and Drug Administration approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
May 1, 2020 FDA has approved a supplemental New Drug Application for Zejula (niraparib) an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a mono¬therapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
Coding
This drug should be coded
